公开(公告)号：US08525712B2

公开(公告)日：2013-09-03

申请号：US13195144

申请日：2011-08-01

Applicant: Takashi Oshima ,  Tatsuji Matsuura ,  Naoki Yada ,  Takahiro Miki ,  Akihiro Kitagawa ,  Tetsuo Matsui ,  Kunihiko Usui

Inventor： Takashi Oshima ,  Tatsuji Matsuura ,  Naoki Yada ,  Takahiro Miki ,  Akihiro Kitagawa ,  Tetsuo Matsui ,  Kunihiko Usui

IPC: H03M1/10

CPC classification number: H03M1/1033 ,  G01S7/4021 ,  G01S13/931 ,  H03M1/167 ,  H03M1/442

Abstract: To improve resolution of a built-in A/D converter by reducing the area occupied by a chip of the built-in A/D converter in a semiconductor integrated circuit that is mounted in an on-vehicle millimeter wave radar device and which incorporates an A/D converter and an MPU. In the semiconductor integrated circuit, a plurality of reception signals of the radar device is A/D-converted by a single digital correction type A/D converter. The digital correction type A/D converter of the single A/D converter is a foreground digital correction type A/D converter that sequentially A/D-converts the reception signals output from a multiplexer of a receiving interface. The single A/D converter includes a pipeline type A/D converter having a plurality of cascade-coupled converters. The semiconductor integrated circuit comprises a correction signal generating unit, a digital correction D/A converter, and a digital correction unit for digital correction.

Abstract translation: 通过在安装在车载毫米波雷达装置中的半导体集成电路中减小内置A / D转换器的芯片所占用的面积来提高内置A / D转换器的分辨率， A / D转换器和MPU。 在半导体集成电路中，由单个数字校正型A / D转换器对雷达装置的多个接收信号进行A / D转换。 单个A / D转换器的数字校正型A / D转换器是从接收接口的多路复用器输出的接收信号顺序进行A / D转换的前景数字校正型A / D转换器。 单个A / D转换器包括具有多个级联耦合转换器的流水线型A / D转换器。 半导体集成电路包括校正信号生成单元，数字校正D / A转换器和用于数字校正的数字校正单元。

公开(公告)号：US07374923B2

公开(公告)日：2008-05-20

申请号：US11593512

申请日：2006-11-07

Applicant: Kunitake Abe ,  Masayoshi Takeda ,  Noboru Yamaji ,  Miyuki Katou ,  Tetsuo Matsui

Inventor： Kunitake Abe ,  Masayoshi Takeda ,  Noboru Yamaji ,  Miyuki Katou ,  Tetsuo Matsui

IPC: C12N9/64 ,  C12N15/57 ,  C12N15/79

CPC classification number: G01N33/74 ,  C07K14/47 ,  G01N33/6893 ,  G01N2500/00 ,  G01N2800/042 ,  G03G15/0882

Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.

Abstract translation: 公开了用于II型糖尿病治疗剂的筛选工具和筛选方法，特别是用于缓解胰岛素抵抗的药剂。 还公开了可用于筛选工具和筛选方法的新型多肽，多核苷酸，载体，启动子和转化体。

公开(公告)号：US06177454B1

公开(公告)日：2001-01-23

申请号：US09514637

申请日：2000-02-29

Applicant: Tatsuya Maruyama ,  Kenichi Onda ,  Masahiko Hayakawa ,  Takumi Takahashi ,  Takayuki Suzuki ,  Tetsuo Matsui

Inventor： Tatsuya Maruyama ,  Kenichi Onda ,  Masahiko Hayakawa ,  Takumi Takahashi ,  Takayuki Suzuki ,  Tetsuo Matsui

IPC: A61K314184

CPC classification number: C07D233/64 ,  C07C217/16 ,  C07C271/16 ,  C07C271/20 ,  C07D235/16 ,  C07D249/12 ,  C07D277/30 ,  C07D277/40 ,  C07D277/42 ,  C07D285/12 ,  C07D471/04

Abstract: An amide derivative represented by the following general formula (I) or a salt thereof and a pharmaceutical composition containing the amide derivative and a pharmaceutically acceptable vehicle. The symbols in the formula have the following meanings wherein A: heteroarylene; X: bond, O, S, —NR5—, —NR5CO—, —NR5CONH—, —NR5SO2— or —NR5C(═NH)NH—; R1: —H, -optionally substituted lower alkyl, -optionally substituted aryl, -optionally substituted heteroaryl or -optionally substituted cycloalkyl; R2a, R2b: —H or -lower alkyl, which may be the same or different; R3: —H or -lower alkyl; R4a, R4b: —H or —OH, which may be the same different, or R4a and R4b are taken together to form ═O or ═N—O—lower alkyl; and R5: —H or -lower alkyl.

Abstract translation: 由以下通式（I）表示的酰胺衍生物或其盐和含有酰胺衍生物和药学上可接受的载体的药物组合物。式中的符号具有以下含义：A：亚杂芳基; X：键，O，S， -NR5-，-NR5CO-，-NR5CONH-，-NR5SO2-或-NR5C（= NH）NH-; R1：-H，可选取代的低级烷基， - 取代的芳基， - 取代的杂芳基或 - 取代的环烷基 ; R 2a，R 2b：-H或 - 低级烷基，其可以相同或不同; R 3：-H或 - 低级烷基; R 4a，R 4b：-H或-OH，其可以相同，或者R 4a和R 4b 一起形成= O或= NO-低级烷基; 和R5：-H或 - 低级烷基。

公开(公告)号：US5543420A

公开(公告)日：1996-08-06

申请号：US295876

申请日：1994-11-01

Applicant: Tomoji Aotsuka ,  Toshiyuki Nishio ,  Hiroshi Hosono ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa

Inventor： Tomoji Aotsuka ,  Toshiyuki Nishio ,  Hiroshi Hosono ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa

IPC: A61K31/47 ,  A61K31/4709 ,  A61P3/08 ,  A61P3/10 ,  A61P13/02 ,  A61P13/12 ,  A61P15/00 ,  A61P25/00 ,  A61P25/02 ,  A61P27/02 ,  A61P27/12 ,  A61P43/00 ,  C07D417/06 ,  A61K31/425 ,  C07D215/227

CPC classification number: C07D417/06

Abstract: A quinoline-3-acetic acid derivative of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom or a substituted or unsubstituted lower alkyl, R.sup.5 is an optionally esterified carboxyl and the broken line means an optional presence of a double bond, and a pharmaceutically acceptable salt thereof. The novel compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and are highly safe. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.

Abstract translation: PCT No.PCT / JP94 / 00007 Sec。 371日期：1994年11月10日 102（e）1994年11月10日日期PCT 1994年1月6日PCT PCT。 第WO94 / 15934号公报 日期：1994年7月21日分子式为其中R 1，R 2和R 3相同或不同并且各自为氢原子或卤素原子的式（I）的喹啉-3-乙酸衍生物，R4为氢原子， 卤素原子或取代或未取代的低级烷基，R 5为任意酯化的羧基，虚线表示任选存在双键，以及其药学上可接受的盐。 本发明式（I）的新化合物及其药学上可接受的盐在包括人的哺乳动物中具有醛糖还原酶的抑制活性，并且是高度安全的。 因此，它们可用作治疗糖尿病并发症的药物组合物，例如角膜损伤，白内障，神经症，视网膜病变和肾病，尤其是白内障和神经症的错综联合。

公开(公告)号：US20120038498A1

公开(公告)日：2012-02-16

申请号：US13195144

申请日：2011-08-01

Applicant: Takashi OSHIMA ,  Tatsuji MATSUURA ,  Naoki YADA ,  Takahiro MIKI ,  Akihiro KITAGAWA ,  Tetsuo MATSUI ,  Kunihiko USUI

Inventor： Takashi OSHIMA ,  Tatsuji MATSUURA ,  Naoki YADA ,  Takahiro MIKI ,  Akihiro KITAGAWA ,  Tetsuo MATSUI ,  Kunihiko USUI

IPC: H03M1/06 ,  H03M1/00

CPC classification number: H03M1/1033 ,  G01S7/4021 ,  G01S13/931 ,  H03M1/167 ,  H03M1/442

Abstract: To improve resolution of a built-in A/D converter by reducing the area occupied by a chip of the built-in A/D converter in a semiconductor integrated circuit that is mounted in an on-vehicle millimeter wave radar device and which incorporates an A/D converter and an MPU. In the semiconductor integrated circuit, a plurality of reception signals of the radar device is A/D-converted by a single digital correction type A/D converter. The digital correction type A/D converter of the single A/D converter is a foreground digital correction type A/D converter that sequentially A/D-converts the reception signals output from a multiplexer of a receiving interface. The single A/D converter includes a pipeline type A/D converter having a plurality of cascade-coupled converters. The semiconductor integrated circuit comprises a correction signal generating unit, a digital correction D/A converter, and a digital correction unit for digital correction.

Abstract translation: 通过在安装在车载毫米波雷达装置中的半导体集成电路中减小内置A / D转换器的芯片所占用的面积来提高内置A / D转换器的分辨率， A / D转换器和MPU。 在半导体集成电路中，由单个数字校正型A / D转换器对雷达装置的多个接收信号进行A / D转换。 单个A / D转换器的数字校正型A / D转换器是从接收接口的多路复用器输出的接收信号顺序进行A / D转换的前景数字校正型A / D转换器。 单个A / D转换器包括具有多个级联耦合转换器的流水线型A / D转换器。 半导体集成电路包括校正信号生成单元，数字校正D / A转换器和用于数字校正的数字校正单元。

公开(公告)号：US07157567B2

公开(公告)日：2007-01-02

申请号：US10491277

申请日：2003-02-19

Applicant: Kunitake Abe ,  Noboru Yamaji ,  Miyuki Katou ,  Tetsuo Matsui

Inventor： Kunitake Abe ,  Noboru Yamaji ,  Miyuki Katou ,  Tetsuo Matsui

IPC: C12N15/57 ,  C12N9/64 ,  C12N15/79

CPC classification number: G01N33/74 ,  C07K14/47 ,  G01N33/6893 ,  G01N2500/00 ,  G01N2800/042 ,  G03G15/0882

Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.

Abstract translation: 公开了用于II型糖尿病治疗剂的筛选工具和筛选方法，特别是用于缓解胰岛素抵抗的药剂。 还公开了可用于筛选工具和筛选方法的新型多肽，多核苷酸，载体，启动子和转化体。

公开(公告)号：US06346532B1

公开(公告)日：2002-02-12

申请号：US09529096

申请日：2000-04-07

Applicant: Tatsuya Maruyama ,  Takayuki Suzuki ,  Kenichi Onda ,  Masahiko Hayakawa ,  Hiroyuki Moritomo ,  Tetsuya Kimizuka ,  Tetsuo Matsui

Inventor： Tatsuya Maruyama ,  Takayuki Suzuki ,  Kenichi Onda ,  Masahiko Hayakawa ,  Hiroyuki Moritomo ,  Tetsuya Kimizuka ,  Tetsuo Matsui

IPC: A61K31495

CPC classification number: C07D231/12 ,  C07D213/30 ,  C07D213/56 ,  C07D213/81 ,  C07D215/48 ,  C07D233/26 ,  C07D235/16 ,  C07D235/30 ,  C07D239/26 ,  C07D241/12 ,  C07D257/04 ,  C07D277/36 ,  C07D277/82 ,  C07D401/04 ,  C07D513/04

Abstract: Amide derivatives represented by general formula (I) or salts thereof wherein each symbol has the following meaning: ring B: an optionally substituted heteroaryl optionally fused with a benzene ring; X: a bond, lower alkylene or lower alkenylene optionally substituted by hydroxy or lower alkyl, carbonyl, or a group represented by —NH— (when X is lower alkylene optionally substituted by lower alkyl which may be bonded to the hydrogen atom bonded to a constituent carbon atom of ring B to form lower alkylene to thereby form a ring); A: a lower alkylene or a group represented by -(lower alkylene)—O—; R1a and R1b: the same or different and each hydrogen or lower alkyl; R2: hydrogen or halogeno; and Z: nitrogen or a group represented by ═CH—. The compounds are useful as a diabetes remedy which not only functions to both accelerate the secretion of insulin and enhance insulin sensitivity but has an antiobestic action and an antihyperlipemic action based on its selective stimulative action on a &bgr;3 receptor.

Abstract translation: 由通式（I）表示的酰胺衍生物或其盐，其中每个符号具有以下含义：环B：任选地与苯环稠合的任选取代的杂芳基; X：任选被羟基或低级烷基取代的低级亚烷基或低级亚烯基，羰基或由-NH-表示的基团（当X为任选被低级烷基取代的低级烷基时，该低级烷基可以键合到与 环B的构成碳原子形成低级亚烷基，从而形成环）; A：低级亚烷基或由 - （低级亚烷基）-O-表示的基团。 R1a和R1b：相同或不同，各个氢或低级烷基; R2：氢或卤素; 和Z：氮或由= CH-表示的基团。 该化合物可用作糖尿病药物，其不仅可以加速胰岛素的分泌并增强胰岛素敏感性，而且具有基于其对β3受体的选择性刺激作用的抗胆碱作用和抗高脂血症作用。

公开(公告)号：US5688818A

公开(公告)日：1997-11-18

申请号：US617824

申请日：1996-03-14

Applicant: Hiroshi Hosono ,  Toshiyuki Nishio ,  Hiromichi Ishikawa ,  Yoshiyuki Nakamura ,  Tetsuo Matsui

Inventor： Hiroshi Hosono ,  Toshiyuki Nishio ,  Hiromichi Ishikawa ,  Yoshiyuki Nakamura ,  Tetsuo Matsui

IPC: A61K31/425 ,  A61K31/428 ,  A61P3/08 ,  A61P3/10 ,  A61P13/02 ,  A61P15/00 ,  A61P25/00 ,  A61P27/02 ,  A61P27/12 ,  A61P43/00 ,  C07D277/64 ,  C07D277/68 ,  C07D277/62

CPC classification number: C07D277/64

Abstract: Provision of a succinamic acid compound of the formula (1) ##STR1## wherein R.sup.1 is an alkyl or a lower alkenyl and R.sup.2 is an optionally esterified carboxyl, a pharmaceutically acceptable salt thereof, an agent for the prophylaxis and/or treatment of the complications of diabetes, comprising, as an active ingredient, the succinamic acid compound or a pharmaceutically acceptable salt thereof, an aldose reductase inhibitor comprising, as an active ingredient, the succinamic acid compound or a pharmaceutically acceptable salt thereof, and a method for producing the succinamic acid compound or a pharmaceutically acceptable salt thereof. The novel succinamic acid compounds of the formula (1) of the present invention and pharmaceutically acceptable salts thereof have a strong aldose reductase activity-inhibitory in mammals such as human, and show superior safety. Hence, they are useful as pharmaceutical agents for the treatment of the complications of diabetes such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis. According to the production method of the present invention, efficient production of such useful compounds of the present invention can be provided.

Abstract translation: PCT No.PCT / JP94 / 01266 Sec。 371日期：1996年3月14日 102（e）1996年3月14日PCT PCT 1994年8月1日PCT公布。 WO95 / 07898 PCT出版物 日期1995年3月23日提供式（1）的琥珀酰胺酸化合物其中R1是烷基或低级烯基，R2是任选酯化的羧基，其药学上可接受的盐， 预防和/或治疗糖尿病的并发症，其包含作为活性成分的琥珀酰胺酸化合物或其药学上可接受的盐，醛糖还原酶抑制剂，其包含作为活性成分的琥珀酰胺酸化合物或其药学上可接受的盐 ，以及琥珀酰胺酸化合物或其药学上可接受的盐的制造方法。 本发明式（1）的新型琥珀酰胺酸化合物及其药学上可接受的盐在哺乳动物如人中具有很强的醛糖还原酶活性，并且具有优异的安全性。 因此，它们可用作治疗糖尿病并发症的药剂，例如角膜损伤，白内障，神经症，视网膜病变和肾病，尤其是白内障和神经症的联合失调。 根据本发明的制造方法，能够有效地制造本发明的有用化合物。

公开(公告)号：US5677300A

公开(公告)日：1997-10-14

申请号：US697917

申请日：1996-09-03

Applicant: Hiroshi Hosono ,  Tomoji Aotsuka ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa

Inventor： Hiroshi Hosono ,  Tomoji Aotsuka ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa

IPC: C07D513/04 ,  A61K31/54 ,  C07D513/06

CPC classification number: C07D513/04

Abstract: A pyridothiazineacetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and a preparation for the prevention and treatment of the complications of diabetes, containing the same. The pyridothiazineacetic acid compound and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as a preparation for the prevention and treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly, cataract and neurosis. In addition, the production method of the present invention enables efficient production of said pyridothiazineacetic acid compound.

Abstract translation: 式（I）的吡啶并噻嗪乙酸化合物其中各符号如说明书中所定义，其药学上可接受的盐，其制备方法和药物组合物，醛糖还原酶抑制剂和预防剂 并治疗糖尿病并发症，含有相同的效果。 本发明的吡啶并噻吩乙酸化合物及其药学上可接受的盐具有醛糖还原酶抑制作用，安全性优异。 因此，它们可用作预防和治疗糖尿病并发症的准备，例如角膜损伤，白内障，神经症，视网膜病变和肾病，尤其是白内障和神经症的联合失调。 此外，本发明的制造方法能够有效地生成所述吡啶并噻嗪乙酸化合物。

公开(公告)号：US5532257A

公开(公告)日：1996-07-02

申请号：US343489

申请日：1994-11-25

Applicant: Takema Hase ,  Takahiro Kumonaka ,  Chikako Shimizu ,  Hiroshi Hosono ,  Tomoji Aotsuka ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa

Inventor： Takema Hase ,  Takahiro Kumonaka ,  Chikako Shimizu ,  Hiroshi Hosono ,  Tomoji Aotsuka ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa

IPC: A61K31/425 ,  A61K31/428 ,  A61P3/08 ,  A61P3/10 ,  A61P43/00 ,  C07C233/25 ,  C07C255/25 ,  C07C321/28 ,  C07D277/64

CPC classification number: C07C255/25 ,  C07D277/64

Abstract: Production of a benzothiazole compound of the formula (I) ##STR1## wherein R.sup.1 is a halogen atom, R.sup.2 and R.sup.3 may be the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom, a lower alkyl, an alkoxy or an alkyl mercapto and R.sup.5 is a hydrogen atom or a lower alkyl, or a pharmaceutically acceptable salt thereof.The compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and have superior safety. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.

Abstract translation: PCT No.PCT / JP94 / 00490 Sec。 371日期：1994年11月25日 102（e）日期1994年11月25日PCT 1994年3月25日PCT公布。 公开号WO94 / 22845 日本公开日1994年10月13日生产式（I）的苯并噻唑化合物其中R 1为卤素原子，R 2和R 3可以相同或不同，各自为氢原子或卤素原子 R4为氢原子，卤素原子，低级烷基，烷氧基或烷基巯基，R5为氢原子或低级烷基或其药学上可接受的盐。 本发明的式（I）化合物及其药学上可接受的盐在包括人的哺乳动物中具有醛糖还原酶的抑制活性，并具有优异的安全性。 因此，它们可用作治疗糖尿病并发症的药物组合物，例如角膜损伤，白内障，神经症，视网膜病变和肾病，尤其是白内障和神经症的错综联合。